Canada: China’s New Foreign Investment Legislation Encourages Participation In Biotech Industry

Last Updated: March 21 2007
Article by Peng Fu and Cheryl V. Reicin

Originally published in The Lawyers Weekly, March 2, 2007.

China offers enormous, but largely unrealized, opportunities for North American biotechnology and pharmaceutical firms. Those looking to either gain a market foothold or acquire complementary capabilities, products and platform technologies may benefit from a low cost base for research and development, liberal policies toward discovery and clinical research, a large pool of qualified researchers and technologists, and ever-increasing government funding and incentives.

Until recently, the vast majority of foreign direct investments in the Chinese biotechnology sector have come from large multinational pharmaceutical companies, and many of those investments have taken the form of joint ventures. However, China’s gradual relaxation of its historical opposition to foreign ownership of domestic companies has prompted firms to look beyond joint ventures as the primary vehicle for participating in the Chinese biotechnology industry.

Mergers and acquisitions (M&As) are becoming the preferred method of participation, because they enable greater control over quality, intellectual property and other strategic issues. High-profile examples of recent deals include Qiagen’s (Hilden, Germany) acquisition of TianWei Times (Beijing) and PG Biotech (Shenzhen); GNI’s (Tokyo, Japan) merger with Shanghai Genomics (Shanghai); and Invitrogen’s (Carlsbad, California) purchase of Shanghai BioAsia Biotechnology (Shanghai).

As biotechnology and pharmaceutical firms are increasingly looking to M&As as a viable strategy for growth, diversification and risk management, the "right" Chinese firms can be expected to garner much attention from Western suitors.

Three recent developments in Chinese law may influence a firm’s decision to enter China.

Regulation on Foreign Investment

As part of its rapidly developing regulatory regime, China recently amended its rules governing the acquisition of domestic companies by foreign investors. The new rules represent a further acceptance of cross-border M&As in line with international practice in that they expressly permit the use of equity consideration in corporate transactions, which was not feasible in the past. This development should be welcomed by research-based or clinical-stage firms that often rely on equity consideration as a primary currency in financing transactions.

Unfortunately, the regulators’ attempt to move quickly to establish a robust regulatory framework has left some ambiguities that may cause concern. For example, the new rules provide an additional layer of scrutiny by the ministry of commerce if the merger "involves any critical industry, affects or may affect the security of [the] national economy, or causes transference of actual control over the domestic enterprise who possesses a resound trademark or China’s time-honored brand." However, the terms "critical industry", "affects", "security of the national economy", "resound trademark", and "time-honored brand" are all undefined and appear to give considerable discretion to regulators to reject or unwind transactions. Commentators have opined that this uncertainty, coupled with existing limits on foreign investment in industries such as energy, communications, media, auto manufacturing and finance, may have a negative impact on the overall level of M&A activity.

Even so, the cost-benefit analysis favours firms’ transacting in the biotechnology industry since foreign investment and participation has, by and large, been encouraged by the Chinese government in the past. There is little indication that this trend would not continue in the future or that the new rules would be used to hinder transactions in this industry.

The key to M&As in China is patience. A deal can take several months longer to close in China than elsewhere because more regulatory approvals are typically needed. Furthermore, foreign firms need to be flexible in dealing with potential targets because the latter would likely be relatively small and unfamiliar with the M&A process. As with all M&A transactions, doing the right homework and taking the right due diligence approach will go a long way to alleviating future difficulties.

Corporate Tax Reform

A longer-term consideration for foreign firms is the Chinese government’s planned unification of corporate tax rates. Reports suggest that lawmakers plan to enact a bill that would eventually unify income tax rates for domestic and foreign companies at 25 per cent. Currently, the rates stand at 15 per cent for foreign companies and 33 per cent for their domestic peers. Even though this reform has resulted in a more costly operating environment, the planned unified rate is still relatively low compared with rates in developed markets.

However, what is more important for biotechnology firms is the accompanying reform to China’s preferential tax policies, which have in the past focused on geographical locations such as designated Hi-Tech Industry Development Zones and Special Economic Zones. The new policies will instead focus on designated industries. Reports suggest that "encouraged" hi-tech enterprises will be eligible for a reduced income tax rate of 15 per cent, and more tax incentives will be granted to start-up companies.

Though the text of the new corporate tax bill and accompanying policies have not yet been released, indications are that the government’s historical support of the biotechnology industry will be retained or strengthened through tax incentives.

Strengthened IP Protection

Any discussion about biotechnology in China must include the issue of IP protection. Indications are that China may have finally turned the corner on this front, as exemplified by the now-famous Viagra (sildenafil citrate) saga. After overturning the Patent Review Board’s decision invalidating Pfizer’s Chinese patents in June 2006, the Beijing No. 1 Intermediate People’s Court again upheld the validity of the patents in December 2006, in an infringement action against two Chinese generic manufacturers.

The very fact that generic companies have gone to court to challenge Pfizer’s patents, instead of simply marketing infringing products, is itself evidence of the maturation of the Chinese IP regime. This, coupled with similar court victories for the likes of Starbucks, Louis Vuitton and Prada in trademark cases, indicates a greater acceptance of the force of IP rights. This should provide some assurance for biotechnology firms looking to invest in China.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.